Results (4304)
A 9-year, Multicentre, Non-interventional, Post-authorisation Safety Study for Patients Prescribed JINARC® for Autosomal Dominant Polycystic Kidney Disease (JINARC PASS)
Austria
Belgium
Finland
France
Germany
Italy
Luxembourg
Netherlands
Norway
Spain
Sweden
Switzerland
United Kingdom
EU PAS number:
EUPAS12842
First published:
06/06/2025
StudyFinalised
Istituti Clinici Scientifici Maugeri IRCCS (ICSM)
First published:
05/06/2025
Italy
Data source
Human
Hospital discharge recordsHospital inpatient recordsPharmacy dispensing recordsNational Diabetes Research Platform Scotland
First published:
05/06/2025
United Kingdom
Data source
Human
OtherPost-marketing Surveillance Study of the Effectiveness and Safety of new Oral Antivirals for outpatients with mild-moderate COVID-19. (ESOA-19)
Portugal
EU PAS number:
EUPAS48186
First published:
05/06/2025
StudyPlanned
Comparative Effectiveness of Ticagrelor vs. Prasugrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Australia
Korea, Republic of
United States
EU PAS number:
EUPAS1000000551
First published:
05/06/2025
StudyOngoing
209452 - A targeted safety study, EPI-ZOSTER-030 VS US DB, to evaluate the safety of Shingrix in adults ≥ 50 years of age in the United States
United States
EU PAS number:
EUPAS37156
First published:
05/06/2025
StudyOngoing
Evaluation of adverse event clusters following immunization with mRNA COVID-19 vaccines: a real-world analysis using EudraVigilance data
Portugal
EU PAS number:
EUPAS43083
First published:
05/06/2025
StudyOngoing
A Non-Interventional Multi-Database Post-Authorisation Study to Assess PregnancyRelated Safety Data from Women with SLE Exposed to Anifrolumab (ROSE PASS)
Denmark
Finland
France
Germany
United States
EU PAS number:
EUPAS108728
First published:
05/06/2025
StudyPlanned
A Non-Interventional Multi-Database Post-Authorisation Study to Assess Pregnancy-Related Safety Data from Women with Severe Asthma Exposed to Tezepelumab (TREATY)
Denmark
France
Sweden
United States
EU PAS number:
EUPAS1000000176
First published:
05/06/2025
StudyPlanned
OPTOMICS - Combining optoacoustic imaging phenotypes and multi-omics to advance diabetes healthcare (Validation Study)
Estonia
EU PAS number:
EUPAS1000000392
First published:
05/06/2025
StudyOngoing
Cross-sectional Study Evaluating the Effectiveness of Venetoclax Risk-Minimisation Measures Among Haematologists in Europe
France
Germany
Poland
Spain
United Kingdom
EU PAS number:
EUPAS104737
First published:
05/06/2025
StudyFinalised
DARWIN EU® - Association between genetic polymorphisms of interest and risk of myopathy among statin users
Estonia
United Kingdom
EU PAS number:
EUPAS1000000369
First published:
05/06/2025
StudyFinalised
Post-Authorisation Safety Study of Paediatric Patients Initiating Selumetinib: A Multiple-Country Prospective Cohort Study
Austria
France
Germany
Israel
Italy
Netherlands
Portugal
Spain
Switzerland
United Kingdom
EU PAS number:
EUPAS45972
First published:
05/06/2025
StudyOngoing
The Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (Gilenya Pregnancy Registry)
Argentina
Australia
Austria
Canada
Cyprus
Czechia
Denmark
Finland
France
Germany
Greece
Hungary
Ireland
Italy
Lebanon
Mexico
Netherlands
Poland
Portugal
Russian Federation
Saudi Arabia
Spain
Sweden
Switzerland
United Arab Emirates
United Kingdom
United States
EU PAS number:
EUPAS2569
First published:
04/06/2025
StudyFinalised
A Post-Authorisation Safety Study of the Utilisation and Prescribing Patterns of Xeljanz® (tofacitinib) Using an Administrative Healthcare Database in France
France
EU PAS number:
EUPAS1000000247
First published:
04/06/2025
StudyOngoing
European Observational Cohort Study of delayed union and non-union fractures of long bones. (COHORTHO-UNION)
France
Germany
Italy
Spain
EU PAS number:
EUPAS1000000535
First published:
04/06/2025
StudyOngoing
Safety and effectiveness of LORLAtinib as a FIRST-line treatment in an ALK-positive Advanced Non-Small Cell Lung Cancer Spanish population. (LORLA-FIRST).
Spain
EU PAS number:
EUPAS1000000406
First published:
04/06/2025
StudyPlanned
213825-Non-interventional (observational) post-licensure study to assess the vaccine effectiveness and safety of recombinant zoster vaccine (RZV) in the rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) patient populations in adults 18 years of age and older (EPI-ZOSTER-044 VE US)
United States
EU PAS number:
EUPAS48157
First published:
04/06/2025
StudyOngoing
Assessing the impact of earlier access to biologics on remission and natural course of asthma (GLEAM)
Argentina
Belgium
Brazil
Bulgaria
Canada
Colombia
Denmark
Estonia
France
Greece
India
Ireland
Italy
Japan
Korea, Republic of
Kuwait
Mexico
Norway
Poland
Portugal
Saudi Arabia
Singapore
Spain
Taiwan
United Arab Emirates
United Kingdom
United States
EU PAS number:
EUPAS1000000530
First published:
04/06/2025
StudyOngoing
Omalizumab in Food Allergy - Retrospective data analysis (OFAR)
Germany
Spain
Switzerland
EU PAS number:
EUPAS1000000585
First published:
04/06/2025
StudyFinalised
Drug Utilization, Adherence, Effectiveness and Resistance: A Prospective Observational Cohort Study in People living with HIV (PLWH) initiating ARV regimen CAB+RPV LA in Collaboration with EuroSIDA (215161)
Albania
Argentina
Austria
Belarus
Belgium
Bosnia and Herzegovina
Croatia
Czechia
Denmark
Estonia
Finland
France
Georgia
Germany
Greece
Hungary
Iceland
Ireland
Israel
Italy
Lithuania
Luxembourg
Netherlands
North Macedonia
Norway
Poland
Portugal
Romania
Russian Federation
Serbia
Slovenia
Spain
Sweden
Switzerland
Ukraine
United Kingdom
EU PAS number:
EUPAS42556
First published:
04/06/2025
StudyOngoing
A Study to Evaluate the Vaccine Effectiveness of Abrysvo® for Preventing RSV Hospitalizations in Adults Aged 60 Years or Above (Complementary Study to DAN-RSV)
Denmark
EU PAS number:
EUPAS1000000480
First published:
04/06/2025
StudyPlanned
Registry study to assess the long-term safety of patients with B lymphocyte malignancies treated with tisagenlecleucel
Australia
Austria
Belgium
Canada
Croatia
Czechia
Denmark
Finland
France
Germany
Greece
Israel
Italy
Korea, Republic of
Netherlands
Norway
Poland
Spain
Switzerland
Taiwan
United Kingdom
United States
EU PAS number:
EUPAS32497
First published:
03/06/2025
StudyOngoing
An Active Safety Surveillance Study to Estimate Incidence Rates of Safety Events of Interest among Patients Treated with Tofacitinib for Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA) within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry in the United States
United States
EU PAS number:
EUPAS103626
First published:
03/06/2025
StudyPlanned
PCSCVM003617/ A Real-World Database Study of Canagliflozin Utilization in Type 1 Diabetes Patients Over Time among European Countries
Belgium
Italy
Spain
United Kingdom
EU PAS number:
EUPAS47585
First published:
03/06/2025
StudyFinalised
A Post-Authorization Safety Study of Atrial Fibrillation Following Respiratory Syncytial Virus Vaccine (ABRYSVOTM) Among Older Adults in the Veterans Affairs Health System (C3671037)
United States
EU PAS number:
EUPAS1000000290
First published:
03/06/2025
StudyOngoing
A Post-Marketing Safety Study using a Pregnancy Registry to Evaluate the Safety of Respiratory Syncytial Virus Vaccine (ABRYSVO™) Exposure During Pregnancy (C3671041)
United States
EU PAS number:
EUPAS1000000179
First published:
03/06/2025
StudyOngoing
Long-term, Non-interventional Study of Recipients of Tecartus for Treatment of Adult Patients With Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL) or Adult Patients With R/R B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
Austria
Canada
Czechia
France
Germany
Israel
Italy
Netherlands
Poland
Portugal
Spain
Switzerland
United Kingdom
United States
EU PAS number:
EUPAS45813
First published:
03/06/2025
StudyOngoing
Medullary Thyroid Carcinoma Surveillance Study: a Case-Series Registry (H9X-MC-B001)
United States
EU PAS number:
EUPAS45076
First published:
03/06/2025
StudyOngoing
A Post-authorization Safety Study to Evaluate the Safety of Multiple Myeloma Patients Treated with Ciltacabtagene Autoleucel
Austria
Brazil
Germany
EU PAS number:
EUPAS49370
First published:
03/06/2025
StudyOngoing
Real-World Impact of Bimekizumab on Disease Activity in axial spondyloarthritis patients including the EARLY subpopulation (EXPEDITE)
Austria
Belgium
European Union
France
Germany
Greece
Italy
Netherlands
Poland
Spain
Switzerland
United Kingdom
EU PAS number:
EUPAS1000000519
First published:
03/06/2025
StudyOngoing
Survey among healthcare professionals treating patients with metastatic breast cancer in selected European countries to evaluate their knowledge on management of hyperglycemia when using alpelisib
Austria
Croatia
Finland
Italy
Luxembourg
Netherlands
Norway
Poland
Slovenia
Spain
Sweden
EU PAS number:
EUPAS42022
First published:
03/06/2025
StudyFinalised
Monitoring safety of Spikevax in pregnancy: an observational study using routinely collected health data in five European countries (COVID-19)
Denmark
Italy
Norway
Spain
United Kingdom
EU PAS number:
EUPAS44450
First published:
03/06/2025
StudyOngoing
Post-Authorization Active Surveillance Safety Study Using Secondary Data to Monitor Real-World Safety of Spikevax in Europe (COVID-19)
Denmark
Italy
Norway
Spain
United Kingdom
EU PAS number:
EUPAS44273
First published:
03/06/2025
StudyFinalised
Real-world post-authorization effectiveness study (PAES) of pembrolizumab for the treatment of NSCLC across races, ethnicities, and age groups (MK-3475-G18)
United States
EU PAS number:
EUPAS1000000576
First published:
03/06/2025
StudyPlanned
DARWIN EU® - Eye disorders in women with breast cancer treated with anastrozole, letrozole or tamoxifen
Croatia
Finland
Germany
Spain
United Kingdom
EU PAS number:
EUPAS1000000599
First published:
03/06/2025
StudyOngoing
Post-authorization safety study of iptacopan in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) using data from the non-interventional IPIG PNH Registry
Canada
China
France
Germany
Italy
Japan
Spain
Switzerland
United Kingdom
United States
EU PAS number:
EUPAS1000000457
First published:
28/05/2025
StudyOngoing
Postmarketing commitment safety study of HZ/su to evaluate pregnancy exposures and outcomes in immunodeficient or immunosuppressed women between 18 and 49 years of age (EPI-ZOSTER-039 VS US DB 214420)
United States
EU PAS number:
EUPAS104070
First published:
27/05/2025
StudyOngoing